Long-term outcomes and pretreatment immune profiling of perioperative toripalimab plus FLOT in gastric or gastroesophageal junction adenocarcinoma: a phase II trial
Long-term outcomes after perioperative immunochemotherapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma remain incompletely characterised. In this single-arm phase II trial (NCT04354662), 51 patients with locally advanced G/GEJ received toripalimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel before surgery with postoperative treatment were enrolled. The reported co-primary endpoints were primary-tumour pathological complete response and 3-year DFS. With median follow-up of 63.1 months, primary-tumour complete response was 19.6% (10/51), whereas nodal-inclusive ypT0N0 response was 13.7% (7/51). Three-year DFS was 52.9% (95% CI, 38.5%-65.5%), 5-year OS was 59.0% (42.9%-71.9%). Grade ≥3 reported treatment-related adverse events occurred in 72.5% of patients. Pretreatment biopsies from 24 patients underwent multiplex immunofluorescence. Higher stromal CD3 positivity was nominally associated with longer survival after median dichotomization, but continuous-variable associations were nonsignificant and no feature survived false-discovery-rate correction. Findings support independent investigation of stromal CD3 positivity but establish neither comparative benefit nor biomarker validity.
Authors
- Fenglin Zang (ORCID: https://orcid.org/0000-0001-9478-7104)
- Jingyu Deng (ORCID: https://orcid.org/0000-0003-4299-1327)
- Yi Ba (ORCID: https://orcid.org/0000-0003-0255-4376)
- Peng Ren (ORCID: https://orcid.org/0000-0002-7495-1883)
- Ting Deng (ORCID: https://orcid.org/0000-0003-4552-8039)
- Feixue Wang (ORCID: https://orcid.org/0000-0003-2091-3424)
- Yue Song (ORCID: https://orcid.org/0000-0003-4499-0387)
- Tao Ning (ORCID: https://orcid.org/0000-0003-4811-3090)
- Ming Bai (ORCID: https://orcid.org/0000-0002-8731-7080)
- Shaohua Ge
- Hongli Li
- Yuchong Yang
- Jiayu Zhang
- Si Yiran
- Likun Zhou
- Rui Liu
- Jing-Jing Duan
- Xiao-Qing Li
- Le Zhang
- Fuliang Cao
- Yansha Sun
- Li-Yan Zhou
- Yi-Lin Deng
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
- First Hospital of China Medical University (CN)
- Tianjin Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11665269/v1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- preprint